Prostate cancer is a global health problem, but incidence varies considerably across
different continents. Asia is traditionally considered a low-incidence area, but the incidence …

Simple Summary DNA damage is one of the hallmarks of cancer. Epithelial ovarian cancer
(EOC)—especially the high-grade serous subtype—harbors a defect in at least one DNA …

PURPOSE Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal
disease with current standard-of-care therapies. Homologous recombination repair (HRR) …

Background Multiple loss-of-function alterations in genes that are involved in DNA repair,
including homologous recombination repair, are associated with response to poly …

Background We previously reported that olaparib led to significantly longer imaging-based
progression-free survival than the physician's choice of enzalutamide or abiraterone among …

The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis,
risk stratification and workup, treatment options for localized disease, and management of …

Context.—Controversies and uncertainty persist in prostate cancer grading. Objective.—To
update grading recommendations. Data Sources.—Critical review of the literature along with …

PURPOSE Germline testing (GT) is a central feature of prostate cancer (PCA) treatment,
management, and hereditary cancer assessment. Critical needs include optimized …

Purpose: Comprehensive genomic profiling (CGP) is of increasing value for patients with
metastatic castration-resistant prostate cancer (mCRPC). mCRPC tends to metastasize to …

Background Patients with metastatic castration-resistant prostate cancer (mCRPC) and
BRCA alterations have poor outcomes. MAGNITUDE found patients with homologous …